NEW YORK (GenomeWeb) – Foundation Medicine and Flatiron Health have formed a collaboration to create an integrated data platform that aims to help firms develop more effective treatments for oncology.
Under the terms of the collaboration, the partners will integrate the cloud-based Flatiron Health OncologyCloud platform with Foundation Medicine's FoundationOne and FoundationOne Heme genomic profiling assays. The companies also plan to co-develop new products based on the combined offering.
The combined solution, which will be available for licensing to life science companies, will enable the integration of genomic, clinical treatment, and outcomes data to support evidence-based drug development and help accelerate the delivery of safe, effective, and targeted new cancer therapies to patients, according to the partners. Licensees will be able to use the new system to better select molecular candidates, design clinical trials more efficiently, and recruit patients faster, they added.
"The marriage of information analytics and cancer genomics represents one of the most powerful opportunities to redefine and reshape the way cancer drugs are developed and delivered to patients in need," Michael Pellini, president and CEO of Foundation Medicine, said in a statement. "The jointly developed information products born from this collaboration will provide life science companies with a powerful new tool to access actionable data that informs the development of targeted new cancer therapies."
The firms expect that products resulting from their collaboration will be commercially available for licensing beginning in mid-2015.